CLINICAL TRIALS PROFILE FOR KENACORT

All Clinical Trials for KENACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02556424 ↗	Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema	Active, not recruiting	Nantes University Hospital	Phase 3	2016-01-01	Corticosteroids, whether injected peri- or intra-ocularly, remain indispensable tools of the therapeutic arsenal in treating inflammatory macular edema. However, a few years ago, only triamcinolone acetonide was available to ophthalmologists. This molecule, developed initially for rheumatological or dermatological use, has been increasingly deployed in ophthalmology, while still off-label. In 2011, the delivery system of dexamethasone from biodegradable and injectable implant into the vitreous cavity obtained the label for inflammatory macular edema. This protocol is therefore designed to compare the efficacy and safety of peri- and intra-ocular injections of corticosteroids in the treatment of inflammatory macular edema.
NCT00999869 ↗	The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata	Unknown status	Siriraj Hospital	N/A	2009-11-01	Alopecia areata is one of the most common cause of non-scarring alopecia. The pathogenesis is still unclear, however, it is believed to be an autoimmune disease. This disease is not a life-threatening condition but it has a significant psychological impact to patient's quality of life. Many triggers have been proposed such as viral infection, stress and neurologic factors. There are many studies show the correlation between disease activities and neurotransmitters level. Substance P and calcitonin gene-related peptide play major role in early stage of disease. These substances cause imbalance of CD4/CD8 lymphocyte in pathologic site and loss of immune privilege of hair follicles. The conventional treatment of alopecia areata with intralesional corticosteroid injection might treat the end of pathogenesis process. There is no therapeutic intervention for the origin of disease. Fortunately, botulinum toxin A could be a novel treatment of alopecia areata. The botulinum toxin A demonstrates inhibition release of substance P in many publications. To sum up, the treatment of alopecia areata with intralesional corticosteroid injection still be a standard treatment, nevertheless, patients have to receive this treatment every month until regrowth of scalp hair. Corticosteroid injection have several side effects, for example, skin atrophy, pigmentary change and hypothalamic-pituitary-adrenal axis suppression. Moreover, injection pain is also affect to psychological aspect . This study purpose is to evaluate the efficacy of botulinum toxin A for alopecia areata and reduce corticosteroid side effects, as well as, others opportunity cost. There is no prospective, randomized-controlled trial of comparison study between botulinum toxin A injection and corticosteroid injection for alopecia areata, therefore, investigators conduct this study for the greatest benefit to alopecia areata patients and for the future research in disease etiology.
NCT00588354 ↗	Epidural Clonidine for Lumbosacral Radiculopathy	Terminated	National Center for Research Resources (NCRR)	N/A	2006-10-01	This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00588354 ↗	Epidural Clonidine for Lumbosacral Radiculopathy	Terminated	Mayo Clinic	N/A	2006-10-01	This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.

Clinical Trial Conditions for KENACORT

Condition Name

Condition Name for KENACORT
Intervention	Trials
Oral Lichen Planus	2
Oral Pemphigus Vulgaris	1
PRP	1
Rheumatoid Arthritis	1

Condition MeSH

Condition MeSH for KENACORT
Intervention	Trials
Lichen Planus, Oral	2
Lichen Planus	2
Spinal Cord Injuries	1
Alopecia	1

Clinical Trial Locations for KENACORT

Trials by Country

+

−

Trials by Country for KENACORT
Location	Trials
Egypt	5
Thailand	2
United States	2
Israel	1
France	1

Trials by US State

+

−

Trials by US State for KENACORT
Location	Trials
New Jersey	1
Minnesota	1

Clinical Trial Progress for KENACORT

Clinical Trial Phase

Clinical Trial Phase for KENACORT
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for KENACORT
Clinical Trial Phase	Trials
Unknown status	4
Completed	4
Recruiting	2

Clinical Trial Sponsors for KENACORT

Sponsor Name

Sponsor Name for KENACORT
Sponsor	Trials
Cairo University	4
Amsterdam Rheumatology and Immunology Center	1
Tel-Aviv Sourasky Medical Center	1

Sponsor Type

Sponsor Type for KENACORT
Sponsor	Trials
Other	13
NIH	1

Clinical Trials, Market Analysis, and Projections for Kenacort (Triamcinolone Acetonide)

Introduction

Kenacort, known generically as triamcinolone acetonide, is a corticosteroid used in various medical applications, including ophthalmology, dermatology, and other inflammatory conditions. This article will delve into the clinical trials, market analysis, and future projections for Kenacort.

Clinical Trials Overview

Ophthalmological Use

In the context of ophthalmology, Kenacort has been studied extensively for its efficacy in treating age-related macular degeneration (ARMD) and choroidal neovascularization (CNV).

• Intravitreal Injection Trials: A prospective, single-center, double-masked, placebo-controlled, randomized clinical trial investigated the use of intravitreal triamcinolone acetonide in patients with subfoveal exudative ARMD. The study found that while the treatment inhibited the growth of subretinal neovascular fronds, it did not significantly reduce the risk of severe visual loss during the first year[1][5].
• Safety Profile: The trials highlighted an acceptable adverse effect profile for a single 4-mg injection of triamcinolone acetonide, with monitoring for intraocular pressure and cataract grading every 6 months for three years. The safety data were reviewed periodically by a Safety Monitoring Committee to ensure no significant differences in severe adverse events between the treatment and placebo groups[5].

Other Clinical Applications

Kenacort is also being explored in other clinical contexts:

• Atopic Dermatitis and T Cell Lymphoma: While not directly related to Kenacort, the broader use of corticosteroids in dermatological conditions like atopic dermatitis is an area of ongoing research. For instance, Corvus Pharmaceuticals is conducting trials on soquelitinib, a selective ITK inhibitor, which, although different, underscores the ongoing interest in immunomodulatory treatments[4].

Market Analysis

Global Export Trends

The global market for Kenacort shows significant activity:

• Export Volume and Growth: From March 2023 to February 2024, there were 640 shipments of Kenacort worldwide, marking a 22% growth rate compared to the preceding year. India, Turkey, and Italy are the top exporters, with India leading the market with 2,821 shipments[2].
• Key Importers: The primary importers of Kenacort include Singapore, Switzerland, and the United Kingdom. This distribution indicates a strong demand for the drug in these regions[2].

Market Dynamics

The biopharmaceutical market is dynamic, with several trends influencing the demand and supply of drugs like Kenacort:

• M&A Activity: The biopharma sector is expected to see sustained M&A activity in 2025, particularly for mid-range transactions. This could impact the market dynamics of specific drugs, although Kenacort, being a well-established product, might not be directly affected by such transactions[3].
• Innovation and Expansion: The expansion into multiomics tools and technologies, as seen with companies like Illumina, indicates a broader trend of innovation in the biopharma sector. While this does not directly impact Kenacort, it reflects the evolving landscape of pharmaceutical research and development[3].

Market Projections

Future Demand

Given the established use of Kenacort in various medical conditions, the demand is likely to remain steady:

• Ophthalmological Needs: The ongoing need for effective treatments for age-related macular degeneration and other ophthalmological conditions will continue to drive the demand for Kenacort.
• Global Health Trends: Increasing healthcare access and awareness in developing countries could lead to an increased demand for corticosteroids like Kenacort.

Competitive Landscape

The market for corticosteroids is competitive, with several products available:

• Generic Competition: The availability of generic versions of triamcinolone acetonide could impact the market share of branded products like Kenacort.
• Innovative Alternatives: The development of new treatments for conditions currently managed with Kenacort could pose a challenge. However, the established safety and efficacy profile of Kenacort is likely to maintain its market position.

Regulatory and Safety Considerations

Safety Monitoring

Clinical trials and post-marketing surveillance have highlighted the importance of safety monitoring for Kenacort, particularly regarding intraocular pressure and cataract formation in ophthalmological use[1][5].

Regulatory Approvals

Kenacort has been approved by various regulatory bodies, and ongoing trials are subject to ethical and regulatory oversight. For example, the studies mentioned were approved by the ethics committees of the University of Sydney and the South Eastern Sydney Area Health Service[1][5].

Key Takeaways

• Clinical Efficacy: Kenacort has shown efficacy in inhibiting the growth of subretinal neovascular fronds but has mixed results in reducing severe visual loss.
• Market Growth: The global market for Kenacort is growing, driven by exports from India, Turkey, and Italy.
• Safety Profile: The drug has an acceptable adverse effect profile, but safety monitoring is crucial.
• Market Dynamics: The biopharma sector's trends, including M&A activity and innovation, may indirectly influence the market for Kenacort.

FAQs

What is Kenacort used for?

Kenacort, or triamcinolone acetonide, is used to treat various inflammatory conditions, including age-related macular degeneration, choroidal neovascularization, and other ophthalmological and dermatological conditions.

What are the key findings from clinical trials on Kenacort?

Clinical trials have shown that Kenacort inhibits the growth of subretinal neovascular fronds but does not significantly reduce the risk of severe visual loss in the first year. The drug has an acceptable adverse effect profile.

Which countries are the top exporters of Kenacort?

India, Turkey, and Italy are the top exporters of Kenacort, with India leading the market.

What are the potential challenges for Kenacort in the market?

The potential challenges include generic competition, the development of innovative alternatives, and regulatory changes.

How is the safety of Kenacort monitored?

The safety of Kenacort is monitored through periodic reviews by a Safety Monitoring Committee, focusing on adverse events such as intraocular pressure changes and cataract formation.

Sources

1. JAMA Ophthalmology: "A Randomized Clinical Trial of a Single Dose of Intravitreal Triamcinolone Acetonide for Age-Related Macular Degeneration"[1].
2. Volza: "Kenacort Exports from World"[2].
3. GEN: "Seven Biopharma Trends to Watch in 2025"[3].
4. Corvus Pharmaceuticals: "Business Update and Reports Financial Results for the First Quarter Ended March 31, 2024"[4].
5. JAMA Network: "Safety of an Intravitreal Injection of Triamcinolone"[5].